SID 2026Abstract 0213Observational study
Minimal clinical benefit with immune checkpoint inhibitor monotherapy rechallenge in ICI-refractory merkel cell carcinoma
A retrospective analysis of 16 patients
Ch'en PY, Zhang Y, Hippe DS, Bhakuni R, Hall ET, Nghiem P
SID Annual Meeting 2026Chicago, 13–16 May 2026 · published in JID 21 Jul 2026
Topics: Skin cancer & tumors
Abstract
The abstract’s text is on the JID website.
DOI 10.1016/j.jid.2026.06.244 · Not in PubMed: details from Crossref